Utilization of dermatologic care by patients with advanced melanoma after initiation of immunotherapy and targeted therapy: A retrospective cohort analysis

Mah Language, 1 J H Shaka and 2 H Yeung 1 Dermatology, Emory University School of Medicine, Atlanta, Georgia, United States and 2 Regional TeleHealth Service, VSN 7, Decatur, Georgia, United States

Patients with advanced stage III and IV melanoma are living longer with the introduction of immunotherapy and targeted therapy. Despite National Comprehensive Cancer Network (NCCN) guidelines recommending regular patient follow up with dermatology for skin checks and nodal assessments, little is known about actual health service use in survivors. This study aims to evaluate dermatologic care utilization by advanced melanoma patients focusing on employment of dermatologic services in order to determine areas of improvement. A retrospective cohort analysis of Stage III and IV melanoma patients with age greater than 18 at the start of follow up (immunotherapy, targeted therapy, or both) who were seen at Dermatology clinic at the Emory Clinic or the Winship Cancer Institute from January 1st, 2011 to September 14, 2020 was done. Data was collected from the Emory Healthcare Clinical Data Warehouse and then validated using manual chart review. Primary outcome is the number of visits to Dermatology clinic per year. Descriptive statistics were done in SPSS. Exponential regression was done on the patients who met study criteria. The majority of patients exclusively received immunotherapy (58) while the minority were exclusively treated with targeted therapy (9) or both (10). The mean age at first dermatology follow up visit was 57.8 years old. The study population included 54.5% males and 45.5% females. The vast majority (90.9%) of patients were Caucasian or White. The mean number of dermatology visits per person-year was 1.9 visits. This did not statistically significantly differ (p = 0.107) between patients treated exclusively with immunotherapy (1.8) and targeted therapy (2.4). Limitations include the fact that many patients obtained their dermatologic care at an outside clinic. Future research should examine optimal dermatologic follow up frequency for patients with advanced stage melanoma after immunotherapy and targeted therapy initiation.

Differences in musculoskeletal impact on health among patients with psoriasis based on disease type, disease severity and undiagnosed psoriatic arthritis (PsA)

G Gondo, S Bell, J Merola and A Gottlieb 1 National Psoriasis Foundation, Portland, Oregon, United States and 2 Division of Dermatology, Department of Medicine, Massachusetts, United States and 3 Ichan School of Medicine at Mount Sinai, New York, New York, United States

The National Psoriasis Foundation conducted a survey within a stratified sample of 1,405 individuals with psoriatic disease in the United States. Participants provided demographics and were asked about a provider diagnosis of psoriasis, PsA, or both. All participants completed the IDPSQI Psoriasis Musculoskeletal (MSK) Symptoms Impact of Disease Questionnaire. PSQI severity was assessed using the Patient Reported Extent of Psoriasis Involvement (PREPI). Participants were screened for undiagnosed PsA using the Psoriasis Epidemiological Screening Tool (PEST). Analysis of variance was used to assess differences in MSK impact across disease diagnosis in 3.5 million participants, while undiagnosed PsA and severity of PsO among individuals with PsO only. Post-hoc tests were conducted to assess difference in MSK impact on health between individuals with Mild PsO (BSA < 3), Moderate PsO (BSA 3 - 10) and Severe PsO (BSA >10). Among the 1,405 respondents, 662 (45.7%) had PsO only, 66 (4.6%) had PsA only and 677 (48.2%) had PsO and PsA. Of those with PsO only, 326 (50.8%) reported having Mild PsO (BSA < 3), 215 (33.5%) reported having Moderate PsO (BSA 3 - 10) and 101 (15.7%) reported having Severe PsO (BSA >10). 201 (31.3%) of the PsO only patients only had a PEST score >3, indicating the presence of undiagnosed PsA. Among participants with PsO only, psoriasis severity was not associated with having a PEST score >3 (p = 0.381), based on results from a chi-square test for independence. Analysis of variance revealed that great MSK impact was associated with having PsA, having more severe PsO and having undiagnosed PsA.

Incidence, co-morbidity burden and resource utilization of psoriasis hospitalization has increased in the last decade: A longitudinal study of the national inpatient sample

E Edigin, P Eseaton, H Shaka and P Ojemolon 1 John H Stroger Hospital of Cook County, Chicago, Illinois, United States, 2 College of Medicine, University of Benin, Benin City, Edo, Nigeria and 3 St. George’s University, St. George’s, Grenada

This study aims to study longitudinal trends of HS hospitalizations over time in the United States (US) using national population data. Data were obtained from the National Inpatient Sample (NIS) database. We performed a retrospective 11-year longitudinal trend analysis of NIS 2008-2018 databases. We searched for index hospitalizations for patients aged≥ 18 years with a principal or secondary diagnosis of HS using ICD codes for the corresponding year. Treatment with only biologic therapy resulted in a significant reduction in non-cutaneous missions and co-morbidity burden of hospitalized HS patients has increased over time in the US. HS itself remained the most common reason for readmission of HS patients during the study period. There was no trend in inpatient mortality of readmitted HS patients after adjusting for co-morbidities. Strategies targeted at improving access to urgent outpatient dermatologic care are essential in preventing unplanned readmissions of HS patients.

Incidence, racial profile, and co-morbidity burden of hidradenitis suppurativa hospitalization has changed in the last decade: A longitudinal study of the national inpatient sample

E Edigin, P Eseaton, PE Ojemolon and H Shaka 1 John H Stroger Hospital of Cook County, Chicago, Illinois, United States, 2 St. George’s University, St. George’s, Grenada and 3 College of Medicine, University of Benin, Benin City, Edo, Nigeria

This study aims to study longitudinal trends of HS hospitalizations over time in the United States (US) using national population data. Data were obtained from the National Inpatient Sample (NIS) database. We performed a retrospective 11-year longitudinal trend analysis of NIS 2008-2018 databases. We searched for index hospitalizations for patients aged≥ 18 years with a principal or secondary diagnosis of HS using ICD codes for the corresponding year. Multivariate logistic and linear regression was used to calculate adjusted p-trend for categorical and continuous outcomes, respectively. The incidence of adult HS hospitalizations in the US increased from 3.5 per 100,000 persons in 2008 to 6.9 per 100,000 persons in 2018 (adjusted p-trend <0.0001), while that of blacks increased from 42.6% in 2008 to 47.7% in 2018 (adjusted p-trend<0.04). The proportion of Hispanics and Asians also increased from 7.1% & 0.5% in 2008 to 9.9% & 1.1% in 2018 (adjusted p-trend <0.001 & 0.004) respectively. The proportion of patients with Charleston co-morbidity index (CCI) score of 0-2 decreased from 68.9% in 2008 to 76.2% in 2018, while those with CCI score of ≥3 increased from 11.1% in 2008 to 23.8% in 2018 (adjusted p-trend <0.0001). Incipient mortality ranged from 0.3% to 0.6% across the years (adjusted p-trend=0.614). The incidence and co-morbidity burden of hospitalizations of HS patients in the US has increased in the last decade. The proportion of hospitalized whites has reduced, with an increase in minorities such as blacks, Hispanics, and Asians. This may be due to minorities having less access to outpatient specialist care, hence increasing their rate of hospitalization. An inter disciplinary approach is essential in managing HS patients.

Biologic and nonbiologic systemic treatment of psoriasis are protective against solid organ, hematologic, and cutaneous cancer in a large multi-institution cohort

N Theodoulakis, N Kleanthous, P Ugwu-Dike, V Pahlavanidis, W Murphy, A Gueves, SG Kwatra and Y Semenov 1 Dermatology, Massachusetts General Hospital, Boston, Massachusetts, United States, 2 Medicine, Dana Farber Cancer Institute, Boston, Massachusetts, United States and 3 Dermatology, Johns Hopkins University, Baltimore, Maryland, United States

Treatment for psoriasis has been augmented in recent decades by the development of biologic and nonbiologic systemic targeting specific inflammatory regulators. Given their recent introduction compared to older systemic immunosuppressants, their impact on patients’ long-term cancer risk has yet to be fully elucidated. We compared the incidence of cutaneous as well as solid organ and hematologic cancer in a large, multi-institutional cohort using an electronic health record (EHR) Research and Analytics (R&A) service. We identified 69,391 psoriatic patients treated between 1/1/1990 and 10/1/2018. Patients with prior cancer history or a competing autoimmune indication for immunomodulation were excluded. A principal or secondary diagnosis of HS is a clinical co-morbidity category that is not for cancer inclusion; however, whether they used biologic therapy only (TNF-a, IL-12,23, or IL-17 inhibitors, n = 4172), nonbiologic systemic therapy only (n=2,739), or any combination of the two (n=1,859). A Cox Proportional Hazards model was used to analyze cancer incidence and competing risks, race, and select comorbidities relative to patients not receiving systemic treatment (n=51.022).

Treatment with only biologic therapy resulted in a significant reduction in non-cutaneous cancer (HR 0.41 [0.32-0.53], p<0.001). A protective effect was also observed with exclusions for solid organ and hematologic cancer (HR 0.64 [0.37-1.07], p=0.031 or any combination of the two (HR 0.60 [0.51-0.70], p<0.001). A similar pattern was observed with cutaneous malignancies, with greater protection observed in patients receiving biologic (HR 0.56 [0.43-0.71], p<0.001) vs. non-decade (HR 0.76 [0.64-0.88], p<0.001) or mixed regimens (HR 0.63 [0.52-0.76], p<0.001). Overall, our study suggests that systemic immunomodulation may reduce cancer incidence in psoriatic patients, particularly in the biologics only group.